GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against solid tumors and infectious diseases, announced today that the U.S. Patent and ...

Kangabio Co. Ltd. has developed and presented data for their EGFRxCD3 TCE prodrug KGX-105 for the treatment of EGFR-expressing solid tumors.